Cellectis (CLLS)

• Market cap: $408M
• 1 day: -0.49%
• 5 days: -7.29%
• 1 month: 0.25%
• 3 months: -9.96%
• 6 months: 104.52%
• Year to date: -15.21%
• 1 year: 169.54%
• 5 years: -87.76%
• 10 years: -81.64%
• Sector: Healthcare
• Industry: Biotechnology

About: Cellectis SA is a clinical stage biotechnological company, employing the core proprietary technologies to develop products based on gene-editing, with a portfolio of allogeneic Chimeric Antigen Receptor T-cells, or UCART, product candidates in the field of immuno-oncology and gene-edited hematopoietic stem and progenitor cells, or HSPC product candidates in other therapeutic indications.

Employees: 222